drugset
drugset / Trial / NCT03137758

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03137758 ↗

Phase 1 Terminated 12 enrolled Pellficure Pharmaceuticals, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of PCUR-101 in combination with androgen suppression therapy in the patients with metastatic CRPC

Timeline

Start
2017-07-24
Primary completion
2019-04-03
Completion
2019-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject PLUMBAGIN Small molecule 50 mg Oral
Subject PLUMBAGIN Small molecule 100 mg Oral
Subject PLUMBAGIN Small molecule 150 mg Oral
Subject PLUMBAGIN Small molecule 200 mg Oral
Subject PLUMBAGIN Small molecule 250 mg Oral
Subject PLUMBAGIN Small molecule 300 mg Oral

Indications

prostate carcinoma